CD209

Summary

CD209 (CD209 molecule, HGNC:1641) is a protein-coding gene on chromosome 19p13.2, encoding CD209 antigen (Q9NNX6). Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response.

This gene encodes a C-type lectin that functions in cell adhesion and pathogen recognition. This receptor recognizes a wide range of evolutionarily divergent pathogens with a large impact on public health, including leprosy and tuberculosis mycobacteria, the Ebola, hepatitis C, HIV-1 and Dengue viruses, and the SARS-CoV acute respiratory syndrome coronavirus. The protein is organized into four distinct domains: a C-terminal carbohydrate recognition domain, a flexible tandem-repeat neck domain, a transmembrane region and an N-terminal cytoplasmic domain involved in internalization. This gene is closely related in terms of both sequence and function to a neighboring gene, CLEC4M (Gene ID: 10332), also known as L-SIGN. The two genes differ in viral recognition and expression patterns, with this gene showing high expression on the surface of dendritic cells. Polymorphisms in the neck region are associated with protection from HIV-1 infection, while single nucleotide polymorphisms in the promoter of this gene are associated with differing resistance and susceptibility to and severity of infectious disease, including rs4804803, which is associated with SARS severity.

Source: NCBI Gene 30835 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 55 total
• Druggable target: yes
• Cancer driver (intOGen): activating (oncogene-like) across 3 cancer types
• MANE Select transcript: NM_021155

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1641
Approved symbol	CD209
Name	CD209 molecule
Location	19p13.2
Locus type	gene with protein product
Status	Approved
Aliases	DC-SIGN, hDC-SIGN, CDSIGN, DC-SIGN1, CLEC4L
Ensembl gene	ENSG00000090659
Ensembl biotype	protein_coding
OMIM	604672
Entrez	30835

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 11 protein_coding

ENST00000204801, ENST00000315591, ENST00000315599, ENST00000354397, ENST00000394161, ENST00000394173, ENST00000593660, ENST00000593821, ENST00000601256, ENST00000601951, ENST00000602261

RefSeq mRNA: 7 — MANE Select: NM_021155 NM_001144893, NM_001144894, NM_001144895, NM_001144896, NM_001144897, NM_001144899, NM_021155

CCDS: CCDS12186, CCDS45949, CCDS45950, CCDS45951, CCDS45952, CCDS59344, CCDS59345

Canonical transcript exons

ENST00000315599 — 7 exons

Exon	Start	End
ENSE00000671477	7746460	7746531
ENSE00001202067	7747306	7747365
ENSE00001724938	7745518	7746087
ENSE00001747548	7744107	7744219
ENSE00002708082	7744941	7745092
ENSE00003108407	7747466	7747534
ENSE00003161653	7739993	7743240

Expression profiles

Bgee: expression breadth ubiquitous, 188 present calls, max score 83.23.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.7169 / max 101.8958, expressed in 171 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178896	0.3302	105
178893	0.2172	76
178895	0.1396	50
178892	0.0165	8
178894	0.0079	3
178891	0.0055	2

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lymph node	UBERON:0000029	83.23	gold quality
superficial temporal artery	UBERON:0001614	82.82	gold quality
decidua	UBERON:0002450	82.18	gold quality
rectum	UBERON:0001052	81.46	gold quality
right coronary artery	UBERON:0001625	80.16	gold quality
ileal mucosa	UBERON:0000331	79.41	gold quality
jejunal mucosa	UBERON:0000399	79.19	gold quality
gall bladder	UBERON:0002110	79.14	gold quality
omental fat pad	UBERON:0010414	78.17	gold quality
peritoneum	UBERON:0002358	78.12	gold quality
apex of heart	UBERON:0002098	77.71	gold quality
duodenum	UBERON:0002114	77.59	gold quality
adipose tissue of abdominal region	UBERON:0007808	77.49	gold quality
synovial joint	UBERON:0002217	76.87	gold quality
vermiform appendix	UBERON:0001154	76.60	gold quality
subcutaneous adipose tissue	UBERON:0002190	76.06	gold quality
smooth muscle tissue	UBERON:0001135	75.61	gold quality
adipose tissue	UBERON:0001013	75.47	gold quality
connective tissue	UBERON:0002384	74.65	gold quality
small intestine	UBERON:0002108	74.32	gold quality
mammary duct	UBERON:0001765	74.25	gold quality
caecum	UBERON:0001153	74.17	gold quality
layer of synovial tissue	UBERON:0007616	74.01	gold quality
parietal pleura	UBERON:0002400	73.96	gold quality
palpebral conjunctiva	UBERON:0001812	73.91	gold quality
mucosa of stomach	UBERON:0001199	73.68	gold quality
epithelium of mammary gland	UBERON:0003244	73.62	gold quality
heart right ventricle	UBERON:0002080	73.60	gold quality
right adrenal gland cortex	UBERON:0035827	73.58	gold quality
placenta	UBERON:0001987	73.55	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.39

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SPI1

miRNA regulators (miRDB)

98 targeting CD209, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-379-3P	99.69	69.60	1524
HSA-MIR-411-3P	99.69	69.63	1524
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-3202	99.66	67.70	2737

Literature-anchored findings (GeneRIF, showing 40)

• Crystal structures of carbohydrate-recognition domains of DC-SIGN bound to oligosaccharide, in combination with binding studies, reveal that it selectively recognizes endogenous high-mannose oligosaccharides (PMID:11739956)
• identification of binding sites for intercellular adhesion molecule 3 and HIV-1 (PMID:11799126)
• DC-SIGN internalizes antigen for presentation to T cells (PMID:11859097)
• DC-SIGN is specifically expressed on IL-4-treated monocytes and is subjected to a tight regulation by numerous cytokines and growth factors. (PMID:11884427)
• interactions with ICAM-3 does not promote DC-SIGN mediated HIV-1 transmission (PMID:12021323)
• carbohydrate/protein recognition profile and other features of DC-SIGN that contribute to the potency of DC to control immunity (PMID:12050176)
• mediates cellular entry by Ebola virus in cis and in trans (PMID:12050398)
• role of CD209 as Leishmania amastigote receptor in human cells (PMID:12122001)
• Review. This article reviews the interaction of DC-SIGN & DC-SIGNR with HIV and Ebola & discusses the mechanism of DC-SIGN-mediated viral transmission. (PMID:12223058)
• Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1 (PMID:12239306)
• DC-SIGN (DC-specific ICAM-3-grabbing nonintegrin) was only expressed by CD14(+)CDla(lo) dermal DCs (PMID:12352970)
• cytomegalovirus envelope glycoprotein B is a viral ligand for DC-SIGN. It extend DC-SIGN implication in virus propagation (PMID:12433371)
• This cell surface receptor discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan (PMID:12496255)
• Mycobacteria target DC-SIGN to suppress dendritic cell function (PMID:12515809)
• DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. (PMID:12515819)
• Expression of DC-SIGN and its ligand, ICAM-3, is found in substantial amounts only in RA synovium, suggesting that their interaction is implicated in the additional activation of synovial macrophages that leads to the production of EMMPRIN and MMP-1. (PMID:12571844)
• Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18- dendritic cell populations in the colonic mucosa of patients with Crohn’s disease (PMID:12594843)
• Appears in the decidua of early pregnancy. (PMID:12598322)
• DC-SIGN may function in pathogen recognition by interaction with the carbohydrate antigens Lex and possibly LDNF, found on important human pathogens, such as schistosomes and the bacterium Helicobacter pylori (PMID:12626400)
• DC-SIGN is an exquisite pathogen-uptake receptor that captures not only viruses but also fungi. (PMID:12645952)
• DC-SIGN facilitates capture and accumulation of HIV-1 viral particles in a vesicular compartment and inhibits viral fusion. Competition between CD4 and DC-SIGN for Env binding likely affects virus access to the cytosol and syncytium formation. (PMID:12692233)
• differential use of DC-SIGN by viral envelope glycoproteins may account for the immunopathogenesis of dengue virus (PMID:12783086)
• DC-SIGN regulation in monocyte-derived macrophages does not singly predict the transmission potential of HIV in this cell type. (PMID:12960240)
• DC-SIGN, can function both as an adhesion receptor and as a phagocytic pathogen-recognition receptor [Review] (PMID:14519388)
• DC-SIGN expression in B-cell lines dramatically enhances viral internalization. (PMID:14576049)
• DC-SIGN is a receptor for promastigote and amastigote infective stages from both visceral (Leishmania infantum) and New World cutaneous (Leishmania pifanoi) Leishmania species, but not for Leishmania major metacyclic promastigotes. (PMID:14707095)
• Organization of DC-SIGN in microdomains on the plasma membrane is important for binding and internalization of virus particles, suggesting that these multimolecular assemblies of DC-SIGN act as a docking site for pathogens like HIV-1 to invade the host (PMID:14709546)
• human DC-SIGN also captures feline immunodeficiency virus via high-affinity (1 nM), Ca(2+)-dependent, D-mannose-inhibited binding to the major envelope glycoprotein, gp95 (PMID:14963164)
• soluble DC-SIGN bound to gp120-Fc more than 100- and 50-fold better than ICAM-2-Fc and ICAM-3-Fc, respectively. Binding sites are described. (PMID:14970226)
• the influx or proliferation of DC-SIGN+ immature and mature DCs and L-SIGN+ cells is dynamically regulated (PMID:15111305)
• data demonstrate for the first time that lectins DC-SIGN and L-SIGN differ in their carbohydrate binding profiles (PMID:15184372)
• immature DCs owe part of their outstanding Ag-independent T cell stimulatory ability to chemokines and ICAM-1, but not DC-specific ICAM-3-grabbing nonintegrin. (PMID:15210758)
• variations in the DC-SIGN repeat region may have a protective effect on transmission of HIV-1 (PMID:15319853)
• expressed on dendritic cells; results demonstrate that hepatitis C pseudoviruses captured by L-SIGN+ or DC-SIGN+ cells efficiently transinfect adjacent human liver cells (PMID:15371595)
• DC-SIGN tetramers are essential for high affinity interactions with pathogens like HIV (PMID:15385553)
• RNA interference of DC-SIGN expression inhibited the attachment of HIV-1 envelope gp120 in dendritic cells (DCs) negative for DC-SIGN and the transfer of HIV-1 from DCs to T cells. (PMID:15452205)
• DC-SIGN specifically interacts with clinical isolates of Aspergillus fumigatus and is involved in the initial stages of pulmonary infection as well as in fungal spreading during invasive aspergillosis. (PMID:15494514)
• extended neck regions stabilize tetramers (PMID:15509576)
• polymorphism in promoter associated with increased risk for parenteral acquisition of Hiv-1 infection (PMID:15564514)
• a role for enhanced avidity during DC-SIGN-mediated intercellular adhesion (PMID:15728245)

Cross-species orthologs

32 orthologs

Organism	Symbol	Gene ID
danio_rerio	asgr1c.2	ENSDARG00000046092
danio_rerio	asgrl1	ENSDARG00000046142
danio_rerio	si:dkey-61f9.1	ENSDARG00000070414
danio_rerio	asgr1a	ENSDARG00000095963
danio_rerio	si:cabz01007816.2	ENSDARG00000102537
danio_rerio	asgr1b	ENSDARG00000103480
danio_rerio	si:ch211-283g2.5	ENSDARG00000108953
danio_rerio		ENSDARG00000111755
danio_rerio		ENSDARG00000112842
mus_musculus	Cd209a	ENSMUSG00000031494
mus_musculus	Cd209d	ENSMUSG00000031495
mus_musculus	Cd209c	ENSMUSG00000040165
mus_musculus	Cd209e	ENSMUSG00000040197
mus_musculus	Cd209b	ENSMUSG00000065987
rattus_norvegicus	Cd209d	ENSRNOG00000001017
rattus_norvegicus	Cd209e	ENSRNOG00000028803
rattus_norvegicus	Clec4m	ENSRNOG00000029881
rattus_norvegicus	Cd209a	ENSRNOG00000040128
rattus_norvegicus	Cd209c	ENSRNOG00000042807
rattus_norvegicus	Cd209al3	ENSRNOG00000062811
rattus_norvegicus		ENSRNOG00000069757
drosophila_melanogaster	tfc	FBGN0035199
drosophila_melanogaster	CG14866	FBGN0038315
drosophila_melanogaster	lectin-46Cb	FBGN0040092
drosophila_melanogaster	lectin-46Ca	FBGN0040093
drosophila_melanogaster	lectin-33A	FBGN0040096
drosophila_melanogaster	CG34033	FBGN0054033
caenorhabditis_elegans	clec-87	WBGENE00007709
caenorhabditis_elegans	clec-91	WBGENE00014117
caenorhabditis_elegans		WBGENE00016088
caenorhabditis_elegans		WBGENE00018692
caenorhabditis_elegans		WBGENE00019606

Paralogs (14): FCER2 (ENSG00000104921), CLEC4M (ENSG00000104938), CLEC4A (ENSG00000111729), CD207 (ENSG00000116031), CLEC10A (ENSG00000132514), ASGR1 (ENSG00000141505), CLEC4F (ENSG00000152672), ASGR2 (ENSG00000161944), CLEC4E (ENSG00000166523), CLEC4D (ENSG00000166527), CLEC4G (ENSG00000182566), CLEC17A (ENSG00000187912), CLEC4C (ENSG00000198178), CLEC6A (ENSG00000205846)

Protein

Protein identifiers

CD209 antigen — Q9NNX6 (reviewed: Q9NNX6)

Alternative names: C-type lectin domain family 4 member L, Dendritic cell-specific ICAM-3-grabbing non-integrin 1

All UniProt accessions (4): Q9NNX6, M0QZG5, M0R0P0, X6RB12

UniProt curated annotations — full annotation on UniProt →

Function. Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response. Thought to mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. The receptor returns to the cell membrane surface and the pathogen-derived antigens are presented to resting T-cells via MHC class II proteins to initiate the adaptive immune response. On dendritic cells (DCs) it is a high affinity receptor for ICAM2 and ICAM3 by binding to mannose-like carbohydrates. May act as a DC rolling receptor that mediates transendothelial migration of DC presursors from blood to tissues by binding endothelial ICAM2. Forms a first contact between DC and resting T cell, througth ICAM3 binding, facilitating the downstream DC-T cell clustering process and DC-induced proliferation of resting T Cells. (Microbial infection) Acts as an attachment receptor for HIV-1 and HIV-2. (Microbial infection) Acts as an attachment receptor for Ebolavirus. (Microbial infection) Acts as an attachment receptor for Cytomegalovirus. (Microbial infection) Acts as an attachment receptor for HCV. (Microbial infection) Acts as an attachment receptor for Dengue virus. (Microbial infection) Acts as an attachment receptor for Measles virus. (Microbial infection) Acts as an attachment receptor for Herpes simplex virus 1. (Microbial infection) Acts as an attachment receptor for Influenzavirus A. (Microbial infection) Acts as an attachment receptor for SARS-CoV. (Microbial infection) Acts as an attachment receptor for Japanese encephalitis virus. (Microbial infection) Acts as an attachment receptor for Lassa virus. Acts as an attachment receptor for Marburg virusn. (Microbial infection) Acts as an attachment receptor for Respiratory syncytial virus. (Microbial infection) Acts as an attachment receptor for Rift valley fever virus and uukuniemi virus. (Microbial infection) Acts as an attachment receptor for West-nile virus. (Microbial infection) Probably recognizes in a calcium-dependent manner high mannose N-linked oligosaccharides in a variety of bacterial pathogen antigens, including Leishmania pifanoi LPG, Lewis-x antigen in Helicobacter pylori LPS, mannose in Klebsiella pneumonae LPS, di-mannose and tri-mannose in Mycobacterium tuberculosis ManLAM and Lewis-x antigen in Schistosoma mansoni SEA. Recognition of M.tuberculosis by dendritic cells occurs partially via this molecule.

Subunit / interactions. Homotetramer. Interacts with C1QBP; the interaction is indicative for a C1q:C1QBP:CD209 signaling complex. Interacts (via C-type lectin domain) with CEACAM1 (via Lewis X moieties); this interaction is regulated by the glycosylation pattern of CEACAM1 on cell types and regulates contact between dendritic cells and neutrophils. (Microbial infection) Interacts with HIV-1 and HIV-2 gp120. (Microbial infection) Interacts with ebolavirus envelope glycoproteins. (Microbial infection) Interacts with cytomegalovirus gB protein. (Microbial infection) Interacts with HCV E2 protein. (Microbial infection) Interacts with dengue virus major envelope protein E. (Microbial infection) Interacts with measles hemagglutinin. (Microbial infection) Interacts with herpes simplex virus 1 surface proteins. (Microbial infection) Interacts with Influenzavirus A hemagglutinin. (Microbial infection) Interacts with SARS-CoV spike glycoprotein. (Microbial infection) Interacts with Japanese encephalitis virus E protein. (Microbial infection) Interacts with Lassa virus Glycoprotein. (Microbial infection) Interacts with marburg virus glycoprotein. (Microbial infection) Interacts with Respiratory syncytial virus glycoprotein G. (Microbial infection) Interacts with Rift valley fever virus and uukuniemi virus envelope glycoprotein. (Microbial infection) Interacts with west-nile virus envelope glycoprotein. (Microbial infection) Interacts with whole M.bovis cells in a Ca(2+)-dependent and independent manner; in vitro experiments suggest it interacts with CH60.1 (groL1), DnaK, GADPH (gap) and LrpG.

Subcellular location. Membrane raft Cell membrane Cell membrane Cell membrane Cell membrane Secreted Secreted Secreted Secreted Secreted Secreted Secreted.

Tissue specificity. Predominantly expressed in dendritic cells and in DC-residing tissues. Also found in placental macrophages, endothelial cells of placental vascular channels, peripheral blood mononuclear cells, and THP-1 monocytes.

Domain organisation. The tandem repeat domain, also called neck domain, mediates oligomerization.

Polymorphism. Genetic variations in the CD209 promoter determine M.tuberculosis susceptibility [MIM:607948]. Genetic variations in CD209 may influence susceptibility or resistance to dengue virus infection, as well as disease progression and severity [MIM:614371]. A promoter polymorphism in the CD209 gene is associated with protection from dengue fever, but not dengue hemorrhagic fever.

Miscellaneous. In vitro, is a receptor for HIV-1 and transmits HIV-1 either in trans without DC infection, or in cis following a DC infection to permissive T-cells to induce a robust infection. Bound HIV-1 remains infectious over a prolonged period of time and it is proposed that bound HIV-1 is not degraded but protected in non-lysosomal acidic organelles within the DCs close to the cell membrane thus contributing to the HIV-1 infectious potential during transport by DCs from the periphery to lymphoid organs. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (12)

UniProt ID	Names	Canonical?
Q9NNX6-1	1, mDC-SIGN1A type I	yes
Q9NNX6-2	2, mDC-SIGN1A type II
Q9NNX6-3	3, mDC-SIGN1A type III
Q9NNX6-4	4, mDC-SIGN1A type IV
Q9NNX6-5	5, mDC-SIGN1B type I
Q9NNX6-6	6, sDC-SIGN1A type I
Q9NNX6-7	7, sDC-SIGN1A type II
Q9NNX6-8	8, sDC-SIGN1A type III
Q9NNX6-9	9, sDC-SIGN1A type IV
Q9NNX6-10	10, sDC-SIGN1B type I
Q9NNX6-11	11, sDC-SIGN1B type II
Q9NNX6-12	12, sDC-SIGN1B type III

RefSeq proteins (7): NP_001138365, NP_001138366, NP_001138367, NP_001138368, NP_001138369, NP_001138371, NP_066978* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001304	C-type_lectin-like	Domain
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR018378	C-type_lectin_CS	Conserved_site
IPR033989	CD209-like_CTLD	Domain
IPR050111	C-type_lectin/snaclec_domain	Family

Pfam: PF00059

UniProt features (63 total): splice variant 12, mutagenesis site 9, repeat 7, strand 7, binding site 6, sequence variant 4, short sequence motif 3, disulfide bond 3, helix 3, topological domain 2, chain 1, domain 1, region of interest 1, transmembrane region 1, glycosylation site 1, sequence conflict 1, turn 1

Structure

Experimental structures (PDB)

14 structures.

PDB	Method	Resolution (Å)
2XR6	X-RAY DIFFRACTION	1.35
2XR5	X-RAY DIFFRACTION	1.42
1SL4	X-RAY DIFFRACTION	1.55
1SL5	X-RAY DIFFRACTION	1.8
9EMQ	X-RAY DIFFRACTION	1.8
9EMR	X-RAY DIFFRACTION	1.9
2IT6	X-RAY DIFFRACTION	1.95
6GHV	X-RAY DIFFRACTION	2.1
7NL7	X-RAY DIFFRACTION	2.1
7NL6	X-RAY DIFFRACTION	2.2
2IT5	X-RAY DIFFRACTION	2.4
1K9I	X-RAY DIFFRACTION	2.5
9EMS	X-RAY DIFFRACTION	2.9
2B6B	ELECTRON MICROSCOPY	25

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NNX6-F1	71.95	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 347; 349; 351; 354; 365; 366

Disulfide bonds (3): 256–267, 284–377, 356–369

Glycosylation sites (1): 80

Mutagenesis-validated functional residues (9):

Position	Phenotype
14–15	loss of antigen internalization by endocytosis.
320	loss of binding to icam3 and hiv-1 gp120.
324	loss of binding to icam3 and hiv-1 gp120.
347	loss of binding to icam3 and hiv-1 gp120.
349	loss of binding to icam3 and hiv-1 gp120.
350	loss of binding to icam3 and hiv-1 gp120.
355	loss of binding to icam3 and hiv-1 gp120.
365	loss of binding to icam3 and hiv-1 gp120.
366	loss of binding to icam3 and hiv-1 gp120.

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-5621575	CD209 (DC-SIGN) signaling
R-HSA-8851680	Butyrophilin (BTN) family interactions
R-HSA-9833110	RSV-host interactions
R-HSA-9918485	Dengue Virus Attachment and Entry
R-HSA-1280218	Adaptive Immune System
R-HSA-1643685	Disease
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-5621481	C-type lectin receptors (CLRs)
R-HSA-5663205	Infectious disease
R-HSA-9820952	Respiratory Syncytial Virus Infection Pathway
R-HSA-9824446	Viral Infection Pathways

MSigDB gene sets: 211 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_HETEROPHILIC_CELL_CELL_ADHESION, GOBP_DENDRITIC_CELL_MIGRATION, MCLACHLAN_DENTAL_CARIES_UP, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, GOCC_CELL_SURFACE, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_ANTIGEN_PROCESSING_AND_PRESENTATION_OF_PEPTIDE_ANTIGEN, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, GOBP_POSITIVE_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_CELL_CELL_ADHESION, GOBP_LEUKOCYTE_MIGRATION

GO Biological Process (22): adaptive immune response (GO:0002250), endocytosis (GO:0006897), immune response (GO:0006955), heterophilic cell-cell adhesion (GO:0007157), leukocyte cell-cell adhesion (GO:0007159), cell-cell recognition (GO:0009988), virion attachment to host cell (GO:0019062), viral genome replication (GO:0019079), antigen processing and presentation (GO:0019882), immature T cell proliferation (GO:0033079), intracellular signal transduction (GO:0035556), dendritic cell migration (GO:0036336), positive regulation of T cell proliferation (GO:0042102), regulation of T cell proliferation (GO:0042129), innate immune response (GO:0045087), symbiont entry into host cell (GO:0046718), peptide antigen transport (GO:0046968), intracellular transport of virus (GO:0075733), B cell adhesion (GO:0097323), positive regulation of viral life cycle (GO:1903902), immune system process (GO:0002376), cell adhesion (GO:0007155)

GO Molecular Function (9): virus receptor activity (GO:0001618), cell adhesion receptor activity (GO:0004895), D-mannose binding (GO:0005537), carbohydrate binding (GO:0030246), pattern recognition receptor activity (GO:0038187), peptide antigen binding (GO:0042605), virion binding (GO:0046790), metal ion binding (GO:0046872), protein binding (GO:0005515)

GO Cellular Component (7): extracellular region (GO:0005576), cytoplasm (GO:0005737), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), membrane (GO:0016020), host cell (GO:0043657)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Immune System	2
C-type lectin receptors (CLRs)	1
Adaptive Immune System	1
Respiratory Syncytial Virus Infection Pathway	1
Dengue Virus Infection	1
Innate Immune System	1
Disease	1
Viral Infection Pathways	1
Infectious disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
viral life cycle	5
cellular anatomical structure	4
T cell proliferation	3
immune response	2
immune system process	2
cell-cell adhesion	2
intracellular anatomical structure	2
signaling receptor activity	2
binding	2
vesicle budding from membrane	1
membrane invagination	1
vesicle-mediated transport	1
import into cell	1
response to stimulus	1
cell recognition	1
adhesion of symbiont to host cell	1
virion binding	1
host cell surface binding	1
viral process	1
signal transduction	1
mononuclear cell migration	1
regulation of T cell proliferation	1
positive regulation of lymphocyte proliferation	1
positive regulation of T cell activation	1
regulation of lymphocyte proliferation	1
regulation of T cell activation	1
defense response to symbiont	1
symbiont entry into host	1
peptide transport	1
antigen processing and presentation of peptide antigen	1
host cell	1
biological process involved in symbiotic interaction	1
transport of virus	1
leukocyte cell-cell adhesion	1
positive regulation of viral process	1
regulation of viral life cycle	1
symbiont entry into host cell	1
exogenous protein binding	1
cell adhesion mediator activity	1
monosaccharide binding	1

Protein interactions and networks

STRING

1928 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CD209	ICAM3	P32942	999
CD209	ITIH4	Q14624	998
CD209	ICAM2	P13598	991
CD209	ERVW-1	Q9UQF0	975
CD209	MUC1	P13931	965
CD209	ITGAM	P11215	960
CD209	CLEC4M	Q9H2X3	920
CD209	ICAM1	P05362	893
CD209	CEACAM5	P06731	887
CD209	LSP1	P33241	885
CD209	LY75	O60449	866
CD209	CD1C	P29017	853
CD209	ENPEP	Q07075	841
CD209	MBL2	P11226	834
CD209	CD4	P01730	812

IntAct

29 interactions, top by confidence:

A	B	Type	Score
S	CD209	psi-mi:“MI:0407”(direct interaction)	0.850
CD209	S	psi-mi:“MI:0407”(direct interaction)	0.850
S	CD209	psi-mi:“MI:0915”(physical association)	0.850
CD209	VAC14	psi-mi:“MI:0915”(physical association)	0.670
VAC14	CD209	psi-mi:“MI:0915”(physical association)	0.670
	CD209	psi-mi:“MI:0915”(physical association)	0.540
CD209		psi-mi:“MI:0407”(direct interaction)	0.540
FAM217B	NCK2	psi-mi:“MI:0914”(association)	0.530
CD209	slpA	psi-mi:“MI:0407”(direct interaction)	0.440
	CD209	psi-mi:“MI:0407”(direct interaction)	0.440
CD209	ICAM3	psi-mi:“MI:0407”(direct interaction)	0.440
CD209	CEACAM1	psi-mi:“MI:0407”(direct interaction)	0.440
S	CD209	psi-mi:“MI:0915”(physical association)	0.400
	LECT2	psi-mi:“MI:0915”(physical association)	0.400
CD209	NCK2	psi-mi:“MI:0914”(association)	0.350
CD209	HMGCR	psi-mi:“MI:0914”(association)	0.350

BioGRID (51): VAC14 (Two-hybrid), CD209 (Affinity Capture-MS), CLEC4M (Affinity Capture-MS), ZNF703 (Affinity Capture-MS), HMGCR (Affinity Capture-MS), HTR1B (Affinity Capture-MS), KLHL26 (Affinity Capture-MS), CLEC4M (Affinity Capture-MS), CD209 (Affinity Capture-MS), HTR1B (Affinity Capture-MS), HMGCR (Affinity Capture-MS), ZNF703 (Affinity Capture-MS), CD209 (Two-hybrid), S (Reconstituted Complex), VAC14 (Two-hybrid)

ESM2 similar proteins: A0A087WUL8, A0A0J9YX57, A0A1B0GV03, A2A6M5, A2A9R3, A5A3E0, A6NEF3, A6NI86, A8MZA4, B4DH59, B5DUH6, D3ZVV1, E9Q0N2, H0YKK7, H0YM25, O04492, O18737, P0C6Y7, P0CG38, P0CG39, P0DPF3, P0DX00, P0DX01, P0DX02, Q3BBV2, Q4R914, Q5TAG4, Q5TI25, Q5W0A0, Q6P3W6, Q6RI63, Q6S8J3, Q86T75, Q86X53, Q8HXZ7, Q8HXZ8, Q8HY00, Q8HY01, Q8HY03, Q8HY11

Diamond homologs: A5PMY6, A6QP79, D3ZWT9, O14594, P02706, P02707, P05451, P06734, P07306, P07307, P07897, P07898, P08290, P08661, P10716, P10758, P11226, P13608, P13611, P16112, P19999, P20693, P22897, P24721, P34927, P41317, P43137, P48304, P49300, P49301, P55066, P55067, P60883, P70194, P81282, P82596, P86854, Q28343, Q28670, Q29011

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
S	“up-regulates activity”	CD209	binding

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 3 cancer types — BRCA, LUSC, STAD.

Clinical variants and AI predictions

ClinVar

55 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	32
Likely benign	10
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

836 predictions. Top by Δscore:

Variant	Effect	Δscore
19:7745510:ATACT:A	donor_loss	1.0000
19:7745511:TACT:T	donor_loss	1.0000
19:7745512:AC:A	donor_loss	1.0000
19:7745513:CT:C	donor_loss	1.0000
19:7745514:T:TA	donor_loss	1.0000
19:7745515:CA:C	donor_loss	1.0000
19:7745516:A:AC	donor_gain	1.0000
19:7745516:AC:A	donor_gain	1.0000
19:7745517:C:CA	donor_loss	1.0000
19:7745517:C:CC	donor_gain	1.0000
19:7745517:CC:C	donor_gain	1.0000
19:7745517:CCCA:C	donor_gain	1.0000
19:7746086:CA:C	acceptor_gain	1.0000
19:7746087:ACT:A	acceptor_loss	1.0000
19:7746088:C:CC	acceptor_gain	1.0000
19:7746089:T:G	acceptor_loss	1.0000
19:7745509:GATAC:G	donor_loss	0.9900
19:7745514:TCACC:T	donor_gain	0.9900
19:7745515:CACCC:C	donor_gain	0.9900
19:7745516:ACC:A	donor_gain	0.9900
19:7745516:ACCCA:A	donor_gain	0.9900
19:7745517:CCC:C	donor_gain	0.9900
19:7745517:CCCAC:C	donor_gain	0.9900
19:7746083:GGACA:G	acceptor_gain	0.9900
19:7746084:GACA:G	acceptor_gain	0.9900
19:7746085:ACA:A	acceptor_gain	0.9900
19:7746086:CAC:C	acceptor_gain	0.9900
19:7746094:C:CT	acceptor_gain	0.9900
19:7746094:C:T	acceptor_gain	0.9900
19:7746095:A:T	acceptor_gain	0.9900

AlphaMissense

2617 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:7743162:C:A	W364C	0.995
19:7743162:C:G	W364C	0.995
19:7743164:A:G	W364R	0.995
19:7743164:A:T	W364R	0.995
19:7743225:C:A	W343C	0.993
19:7743225:C:G	W343C	0.993
19:7744990:C:T	C284Y	0.992
19:7745061:C:A	W260C	0.992
19:7745061:C:G	W260C	0.992
19:7744133:C:A	W329C	0.991
19:7744133:C:G	W329C	0.991
19:7743124:C:G	C377S	0.990
19:7743125:A:T	C377S	0.990
19:7744175:C:A	W315C	0.990
19:7744175:C:G	W315C	0.990
19:7744990:C:G	C284S	0.990
19:7744991:A:T	C284S	0.990
19:7743124:C:T	C377Y	0.989
19:7744989:G:C	C284W	0.988
19:7744139:C:A	W327C	0.987
19:7744139:C:G	W327C	0.987
19:7744991:A:G	C284R	0.987
19:7745063:A:G	W260R	0.987
19:7745063:A:T	W260R	0.987
19:7743125:A:G	C377R	0.986
19:7743148:C:G	C369S	0.986
19:7743149:A:T	C369S	0.986
19:7743187:C:G	C356S	0.985
19:7743188:A:T	C356S	0.985
19:7744135:A:G	W329R	0.985

dbSNP variants (sampled 300 via entrez): RS1000176268 (19:7746584 C>T), RS1000615810 (19:7742705 A>G), RS1000683602 (19:7745077 G>A,C), RS1001617290 (19:7743868 C>T), RS1001680981 (19:7743361 C>G), RS1001835178 (19:7748975 G>A), RS1002651304 (19:7744751 A>C), RS1002790776 (19:7743554 A>G), RS1003686123 (19:7745762 C>G,T), RS1003743319 (19:7742057 G>A), RS1004027727 (19:7748106 C>T), RS1004394238 (19:7744375 G>A), RS1004477152 (19:7740424 A>G,T), RS1004657417 (19:7747234 C>A,G,T), RS1004691573 (19:7746939 C>A,T)

Disease associations

OMIM: gene MIM:604672 | disease phenotypes: MIM:609423, MIM:614371

GenCC curated gene-disease

Mondo (2): susceptibility to HIV infection (MONDO:0004951), dengue virus, susceptibility to (MONDO:0013713)

Orphanet (1): Dengue fever (Orphanet:99828)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006585_2899	Blood protein levels	2.000000e-35

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1795114 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — C-type lectin-like receptors (CLRs)

ChEMBL bioactivities

6 potent at pChembl≥5 of 16 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.78	Kd	166	nM	CHEMBL5560458
6.51	IC50	310	nM	CHEMBL4289617
6.16	Kd	692	nM	CHEMBL6174105
6.12	Kd	764	nM	CHEMBL5562846
5.70	Kd	2000	nM	CHEMBL1503347
5.64	Kd	2310	nM	CHEMBL6150919

PubChem BioAssay actives

4 with measured affinity, of 82 total; 4 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-acetamido-3-[1-[2-[2-[2-[[1-[2-[(2S,3S,4S,5R,6R)-4-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxyethyl]triazol-4-yl]methoxy]ethoxy]ethoxy]ethyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-4-amino-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid	2080412: Binding affinity to human DC-SIGN CRD (264 to 399 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as dissociation constant by SPR analysis	kd	0.1660	uM
4-[3-[3-oxo-6-(4-pyridin-4-ylpiperazine-1-carbonyl)-2,4-dihydro-1H-quinoxalin-2-yl]propyl]benzenesulfonamide	1418327: Inhibition of DC-SIGN (unknown origin) after 1 hr by fluorescence analysis	ic50	0.3100	uM
(4S)-4-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-amino-3-[1-[2-[2-[2-[[1-[2-[(2S,3S,4S,5R,6R)-4-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxyethyl]triazol-4-yl]methoxy]ethoxy]ethoxy]ethyl]-2,5-dioxopyrrolidin-3-yl]sulfanyl-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid	2080412: Binding affinity to human DC-SIGN CRD (264 to 399 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as dissociation constant by SPR analysis	kd	0.7640	uM
7-[4-(2-methoxyphenyl)piperazine-1-carbonyl]-3-[(2-methylphenyl)methylsulfanylmethyl]-3,4-dihydro-1H-quinoxalin-2-one	1571764: Binding affinity to human DC-SIGN ECD expressed in Escherichia coli BL21(DE3) after 1 hr by Man-Fl-BSA assay	kd	2.0000	uM

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
deoxynivalenol	decreases expression	1
sodium arsenite	affects cotreatment, decreases reaction, increases expression	1
ferrous chloride	increases expression	1
nivalenol	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	1
15-acetyldeoxynivalenol	decreases expression	1
CGP 52608	affects binding, increases reaction	1
FSL-1 lipoprotein, synthetic	increases expression, decreases reaction	1
BH30sucMan	affects activity	1
bisphenol S	increases methylation	1
Resveratrol	decreases reaction, increases expression, decreases expression	1
Air Pollutants	increases expression	1
Cadmium	increases expression	1
Succimer	increases expression, affects cotreatment	1
Lead	increases expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Methotrexate	decreases expression	1
Nickel	increases expression	1
Phthalic Acids	decreases methylation	1
Ziram	increases expression	1
Asbestos, Serpentine	decreases expression	1
Zinc Sulfate	increases expression	1
Magnetite Nanoparticles	increases expression, affects cotreatment	1

ChEMBL screening assays

21 unique, capped per target: 21 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1805238	Binding	Binding affinity to Fc-IgG-tagged DC-SIGN carbohydrate recognizing domain at 1 mM	FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. — J Med Chem

Cellosaurus cell lines

11 cell lines: 10 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0R20	B-THP-1/DC-SIGN	Cancer cell line	Male
CVCL_0R21	THP-1/DC-SIGN	Cancer cell line	Male
CVCL_0R22	Raji/DC-SIGN	Cancer cell line	Male
CVCL_0R23	NIH 3T3/DC-SIGN	Spontaneously immortalized cell line	Male
CVCL_0R26	THP-1(NCI)/DC-SIGN	Cancer cell line	Male
CVCL_2Z95	U937-DC-SIGN	Cancer cell line	Male
CVCL_B8CW	Abcam HCT 116 CD209 KO	Cancer cell line	Male
CVCL_B8TL	Abcam MCF-7 CD209 KO	Cancer cell line	Female
CVCL_B9F4	Abcam A-549 CD209 KO	Cancer cell line	Male
CVCL_S546	Ramos/DC-SIGN	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.